RxDoctor Payments Data

Derek Michaelis

Optometrist · Duluth, MNNPI 1932764883

Payments from drug & device makers

$657in general payments, 2019–2025

Across 23 payments — averaging $28.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$143
  • Alcon$121
  • Rxsight Inc$92
  • Tarsus Pharmaceuticals, Inc.$66
  • Johnson & Johnson Surgical Vision, Inc.$49
  • AbbVie$39
  • plus $147 from 6 others

What the payments were for

  • Food & beverage$657100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$657 in reported general payments places this provider in the 70th percentile of 826 optometrist providers in Minnesota.

See all optometrist providers in Minnesota

Medicare billing

Part B allowed, 2024
$65,535
Medicare patients
351
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner35$64,251
RestasisCyclosporine35$55,732
XiidraLifitegrast24$35,423
Cyclosporine18$16,295
TyrvayaVarenicline Tartrate20$14,124
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$3,890
RocklatanNetarsudil Mesylat/Latanoprost11$3,673
Latanoprost173$2,571
Brimonidine Tartrate19$2,548
Prednisolone Acetate40$1,843
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat78$1,801
Pilocarpine Hcl15$1,238
Timolol Maleate104$1,215
ErythromycinErythromycin Base60$757
ValacyclovirValacyclovir Hcl15$663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$66$64,25135 claims
AbbVieRestasis$39$55,73235 claims
Oyster Point Pharma, Inc.Tyrvaya$27$14,12420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 826 optometrist providers in Minnesota.

Other optometrist in Duluth

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →